Rafijul Bari

Title: Rafijul Bari: Innovator in Cancer Treatment

Introduction

Rafijul Bari is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment through his innovative inventions. With a total of 3 patents, Bari's work focuses on advancing therapeutic methods for cancer care.

Latest Patents

One of his latest patents is a method for NK cell transduction. This invention discloses an in-vitro method for transferring biological material into activated NK cells using a pseudotyped retroviral vector particle or a virus-like particle. The process involves activating NK cells and adding the vector particle, which comprises a modified baboon endogenous retrovirus envelope glycoprotein. This allows for the effective transfer of biological material into the activated NK cells. Another significant patent is a chimeric antigen receptor specific for the BDCA2 antigen. This invention includes an antigen binding domain specific for BDCA2 and engineered cells expressing this CAR, aimed at treating cancers such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Career Highlights

Throughout his career, Rafijul Bari has worked with reputable organizations, including Miltenyi Biotec B.V. and St. Jude Children's Research Hospital. His experience in these institutions has contributed to his expertise in the field of cancer research and treatment.

Collaborations

Bari has collaborated with notable coworkers such as Wing Leung and Markus Granzin. These partnerships have further enhanced his research and development efforts in innovative cancer therapies.

Conclusion

Rafijul Bari is a distinguished inventor whose work in cancer treatment is paving the way for new therapeutic approaches. His patents reflect a commitment to advancing medical science and improving patient outcomes.